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Summary: 4-Methylumbelliferyl-cC-D-N-sulphoglucosaminide (MU-a-GlcNS) was 
synthesized and shown to be a substrate for the lysosomal heparin sulphamidase. 
Sanfilippo A patients' fibroblasts (n=42) and lymphocytes (n= 1) showed 0-3% of 
mean normal heparin sulphamidase activity; in total eukocytes from patients (n = 8) 
sulphamidase activity was clearly deficient. In fibroblasts from obligate hetero- 
zygotes for Sanfilippo A, the sulphamidase activity was reduced in 9 out of 10 cases. 
Heparin sulphamidase desulphates MU-c~GlcNS to MU-aGIcNH 2 and further 
hydrolysis during a second incubation is required to liberate 4-methylumbelliferone, 
which can be measured. Yeast a-glucosidase, which has low but sufficient 
a-glucosaminidase activity, was used to hydrolyse the reaction intermediate 
MU-c~GlcNH z to release 4-methylumbelliferone a dfree glucosamine. 
Sanfilippo disease (mucopolysaccharidosis type III, MPS III) comprises four different 
autosomal recessive subtypes (for review see Neufeld and Muenzer 1995) and is clinically 
characterized by severe central nervous system degeneration but only mild somatic 
abnormalities. Owing to different defects in the degradation of heparan sulphate, patients 
store excessive amounts of this mucopolysaccharide in various tissues. 
MPS III type A is caused by a deficiency of heparin sulphamidase (EC 3.10.1.1; Kresse 
et al 1973). Although the mucopolysaccharidoses ar  rare disorders, MPS IIIA is relatively 
common. Heparin sulphamidase i  routinely assayed using [N-35S-sulphonate]heparin 
(Kresse et al 1973). This assay has many pitfalls related to the instability and short half- 
life of the substrate and the poor relationship between amount of enzyme and activity. 
The use of [3H]heparin-derived oligosaccharides has overcome most of these difficulties 
(Hopwood and Elliot 1981 a,b, 1982). 
In this paper we describe a novel, simple fluorimetric assay for heparin sulphamidase, 
using 4-methylumbelliferyl-a-D-N-sulphoglucosaminide, and show its usefulness in the 
diagnosis of MPS IliA. 
278 
Fluorimetric enzyme assay Jbr MPS IliA 279 
MATERIALS AND METHODS 
4-Methylumbelliferyl-a-D-N-sulphoglucosaminide (MU-aGlcNS; 2-sulphamino-2-deoxy- 
D-glucopyranosyl cd-[4-methylumbelliferone]) has been synthesized by selective N- 
sulphation of the free amino group in 4-methylumbelliferyl-a-D-glucosaminide by an excess 
of triethylamine-sulphur trioxide complex in diInethylformamide-methanol solution. 
After purification of the resulting mixture, by passing through acation exchange resin and 
substitution of triethylamino group to sodium, the product was lyophilized. The synthesis 
of starting material with free amino group was described earlier (Voznyi et al 1991). 
Total leukocytes were isolated from heparinized blood as described previously (van 
Diggelen et al 1990), and lymphocytes were prepared using LymphoSep (tCN Flow). The 
white blood cells were frozen before use. Skin fibroblasts were cultured according to 
routine procedures inHam's F10 medium supplemented with 15% fetal bovine serum and 
antibiotics. The cells were harvested with trypsin 7 days after the last subculture and stored 
at -80°C until use. Fibroblasts from patients with Sanfilippo types A, B, C and D or 
multiple sulphatase deficiency were obtained from the European Human Cell Bank, 
Rotterdam, The Netherlands (Dr W. J. Kleijer). 
Homogenates were prepared by sonication of cell material in water. The standard 
heparin sulphamidase r action mixtures for fibroblasts and lymphocytes consisted of 10/11 
homogenate (10 or 15 yg protein, respectively) and 20/11 MU-c~GlcNS (5 or 10 mmol/L, 
respectively) in Michaelis' barbital sodium acetate buffer, pH 6.5 (29mmol/L sodium 
barbital, 29mmot/L sodium acetate, 0.68% (w/v) NaCI, 0.02% (w/v) sodium azide; adjusted 
to pH 6.5 with HC1) and the reaction mixtures were incubated for t7h at 37°C or 47°C, 
respectively. MU-aGlcNS is available from Moscerdam Substrates (for inquiries: O.R van 
Diggelen, Rotterdam). The standard assay for leukocytes was different: 10#1 homogenate 
(60,ug protein) plus 20/~1 10mmol/L MU-aGIcNS in barbital/sodium acetate buffer, pH 
6.5 (see above), containing 0.225 mg/ml Pefabloc (a protease inhibitor from Boehringer; 
not stable in solution) was incubated for 17h at 47°C. For all assays, after the first incubation 
at either 37°C or 47°C, 6yl twice-concentrated Mctlvain's phosphate/citrate buffer, pH 
6.7, containing 0.02% sodium azide and 10,ul (0.1 U) yeast a-glucosidase (Sigma) in water 
were added and a second incubation of 24h at 37°C was carried out. Long incubations at 
37°C (17-24h) were carried out in 96-well titreplates which were sealed airtight with 
broad sticky tape, limiting evaporation to< 15%. Incubations at 47°C were carried out, in 
Eppendorf tubes, under oil, to prevent evaporation; after the first incubation, the mixtures 
were transferred quantitatively to the wells of a titreplate and the second incubation was 
carried out as described above. 
Next, 200]11 0.5 mob% Na2CO3/NaHCO r pH 10.7, was added and the fluorescence ofthe 
released 4-methylumbelliferone (MU) was measured on a Fluoroskan (Titertek) fluorimeter. 
Protein was determined as described previously (van Diggelen et al 1990). 
RESULTS 
The potential of 4-methylumbelliferyl-a-D-N-sulphoglucosaminide (MU-aGIcNS) as 
substrate for the heparin sulphamidase was investigated. The liberation of MU from MU- 
aGlcNS cannot be accomplished by the sole action of heparin sulphamidase, since this 
enzyme only cleaves the N-sulphate, yielding MU-aGlcNH 2. In previous tudies we had 
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Figure 1 pH-dependence of heparin sulphamidase activity. Fibroblasts from a control (A) and a 
Sanfilippo A patient (A); leukocytes from a control ([~) and a Sanfilippo patient (ll). Triangles, left 
scale; squares, right scale. Reaction conditions as in standard assay, except for pH 
found that a-glucosidase from various ources has low, but significant, a-glucosaminidase 
activity towards MU-a-GlcNH 2, releasing free glucosamine (Wang He et al, unpublished 
observation). We applied this observation to our sulphamidase assay by subjecting the 
reaction mixtures to a second incubation (24h at 37°C) in the presence of 0.1U yeast 
a-glucosidase, which caused complete hydrolysis of the reaction intermediate MU-a- 
GlcNH 2 between 10 and 1000pmol. 
In the experiments described below, heparin sulphamidase wasassayed under standard 
conditions in barbital/sodium acetate buffer as described in the Materials and Methods 
section (except for the condition which was being investigated). The pH optimum of 
heparin sutphamidase from fibroblasts and leukocytes was pH 6.5, whereas fibroblasts and 
leukocytes from a Sanfilippo A patient had practically no activity in the pH range tested 
(Figure 1). The apparent K m was  estimated to be 4mmol/L for fibroblasts and 8 mmol/L 
for teukocytes (Figure 2). The sulphamidase activity increased nearly linearly with protein 
up to 20pg for fibroblasts and up to 60¢tg for leukocytes (Figure 3). A nearly linear rate 
of reaction was observed over a period of up to 17 h incubation (Figure 4). Michaelis' 
barbital/sodium acetate buffer was the only buffer found useful at pH 6.5, since the more 
commonly used buffers were inhibitory (Table 2). Phosphates and sulphates are also 
powerful inhibitors in our standard sulphamidase assay (Table 2). 
Under the standard conditions f fibroblast assay, heparin sulphamidase activity was 
readily detectable in lymphocytes but barely detectable in total leukocytes. Compared to 
fibroblasts and lymphocytes, the activity in leukocytes was unexpectedly ow, and we 
considered that sulphamidase was being degraded by granulocyte proteases during the 
long incubation at a neutral pH (6.5), Several protease inhibitors were tested and a mixture 
prepared by Boehringer (Pefabloc) greatly increased sulphamidase activity. Heparin 
sulphamidase is a velaj heat-stable nzyme, and this has been exploited to increase 
sulphamidase activity by incubation at elevated temperatures (Whiteman and Young 1977; 
Hopwood and Elliott 1981a,b, 1982). In our assay, raising the incubation temperature from 
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Figure 2 Lineweaver-Burk plot for heparin sulphamidase activity with MU-aGlcNS, Normal 
fibroblasts (upper panel) and leukocytes (lower panel). V is in units of nmol/17 h per mg protein. 
Reaction conditions as in standard assay, except fbr MU-aGlcNS concentration 
37°C to 47°C resulted in 2- to 3-fold increase. The addition of Pefabloc in the 47°C assay 
ted to a 3-fold increase of sulphamidase activity in leukocytes, with an optimum effect 
obtained between 0.1 and 0.3 mg/ml. At higher concentrations it was inhibitory. Using the 
protease inhibitor Pefabloc, heparin sulphamidase activity could be measured reliably in 
total leukocytes. (The method is described as the standard leukocyte assay under Materials 
and Methods.) Dialysis of leukocyte homogenate did not increase the sulphamidase 
activity appreciably. Increasing the incubation temperature from 37°C to 47°C caused a 
t .5- to 2-fold increase in sulphamidase activity of lymphocytes and fibroblasts, Since the 
activity in fibroblasts at 37°C is high, this standard incubation temperature is to be 
preferred for diagnostic laboratories. 
The heparin sulphamidase activity was determined in material from patients and 
controls under standard assay conditions. Sulphamidase activity in fibroblasts and lympho- 
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Figure 3 Protein dependence of heparin sulphamidase activity. Normal fibroblasts (A: left scale) 
and leukocytes (D; right scale). Reaction conditions as in standard assay, except for amount of protein 
6 
60 
4 
E 4C 
_> 
2c 
0 zi 8 12 1"6 2"0 24 
Incubation time (hours) 
Figure 4 Time course of heparin sulphamidase activity. Normal fibroblasts (~; left scale) and 
leukocytes (5;  right scale). Reaction conditions as in standard assay, except for incubation time 
cytes from MPS IIIA patients was 0-3% of mean control activity (Table 1). The residual 
activity in total leukocytes from MPS IIIA patients was 0-10%, Fibroblasts from patients 
with multiple sulphatase deficiency had 0.7-3.4% activity, whereas patients with Sanfilippo 
disease types B and C had normal sulphamidase activity. Surprisingly, all three patients 
with Sanfilippo D had reduced sulphamidase activity in the range for heterozygotes of 
MPS IIIA (Table I). 
DISCUSSION 
We have defined conditions for the fluorimetric determination f heparin suIphamidase in 
a two-step assay, using the substrate 4-methytumbeltiferyl-a-D-N-sulphoglucosaminide 
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Table 1 Heparin sulphamidase activity in fibroblasts and leukoeytes 
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Heparin sutphamidase activity (nmol}17 h per mg protein) 
FibrobIasts Leukocytes Lymphocytes 
No~nal range 42- 152 (n=28) 1.8 -6.8 (n= 11) 11-20 (n=7) 
(mean -+ SD) (68 + 24) (4.1 + 1.4) (13.7 + 3.3) 
MPS IliA patients, range 0.0-2.2 (n=42) 0.0-0.4 (n=8) 0.3 (n= 1) 
MPS IIIA carriers, range 15-43 (n= 10) 
(mean _+ SD) (31 + 7) 
Multiple sulphatase deficiency 0.5; 2.3 (n=2) 
MPS IIIB 66 (n = 1) 
MPS IIIC 73 (n = 1) 
MPS IIID 26; 32; 38 (n=3) 
Table 2 Inhibitors of heparin sulphamidase activity 
Relative 
suIphamidase activity (%) 
Various buffers at pH 5.8 
Sodium acetate 100 
Michaelis' barbitalJsodium acetate 100 
Gomori's Tris/maleate < 5 
Sodium citrate/NaOtt 10 
Sodium citrate/citric acid 10 
Imidazole/HC1 50 
Anions in barbital/sodium acetate 
Sulphate (0.1 mol/L) 
Phosphate (0.1 mol/L 
1.5 
2 
(MU-aGlcNS). Desulphation ~s accomplished by heparin sutphamidase and the fluoro- 
chrome MU is released from the reaction intermediate (MU-aGlcNH2) during a second 
incubation with a-glucosidase, which also has a-glucosaminidase activity (Wang tte et al, 
unpublished observation). 
MU-aGlcNS was shown to be useful in the diagnosis of Sanfilippo type A disease. The 
residual heparin sulphamidase activity in fibroblasts, leukocytes or lymphocytes from the 
48 MPS IliA patients investigated was 0-3 % of the mean control activity. 35S-Radiolabelled 
heparin is by far the most widely used substrate for assay of heparin sulphamidase. This 
method, originally described by Kresse et al (1973), is inconvenient because the substrate 
has a short half-life and it needs to be repurified regularly. Furthermore, separation 
techniques are required to isolate the reaction product; the relationship between amount of 
protein and enzyme activity is poor; and reproducibility of the assay occasionally causes 
problems, e.g. high residual activity in MPS IIIA patients. Our fluorogenic assay is 
sensitive (Table 1), requiring only 10/~g protein from a fibroblast homogenate, and specific 
with low residual activity in patients (<3%). It is obviously more convenient than the 
conventional ssay. The assay, which was adequate for fibroblast and lymphocytes, was 
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too insensitive for total eukocytes. Since leukocytes are the most widely used material for 
enzyme analysis, we have modified the assay to increase the activity in control eukocytes. 
These modifications, raising the incubation temperature to 47°C, increasing the substrate 
concentration, and adding the protease inhibitor Pefabloc (Boehringer, unpublished 
composition), allowed determination of heparin sulphamidase deficiency in MPS IIIA 
patients. Occasionally the residual activity was rather high (10%, Table 1). 
Carrier detection in fibroblasts with this assay was informative in 9 out of t0 of the 
obligate heterozygotes having reduced sulphamidase activity. 
The natural substrate for heparin sutphamidase is polymeric heparin or heparan sulphate; 
thus heparin sulphamidase is always exposed to the terminal oligomeric stretch of heparin. 
Hopwood and co-workers (Hopwood and Elliott 1981a,b; Freeman and Hopwood 1986) 
have prepared a series of di-, tri- and tetrasaccharides rived from heparin, and investigated 
the importance of the saccharides adjacent to the terminal N-sulphated glucosamine. Using 
a series of structurally different disaccharides, it was shown that the presence of a C-6 
carboxyl group and a C-2 O-sulphate on the adjacent uronic acid moiety increased 
sulphamidase activity 100-800 times. Increasing the substrate l ngth by two residues led 
to a 10-fold increased sulphamidase activity, relative to the best disaccharide substrate 
(Hopwood and Elliott 1982); free GlcNS was not de-N-sulphated under these conditions 
(Hopwood and Elliott 1981b). These results implied an essential role for the structure of 
the adjacent residues in the mechanism of action or binding of sulphamidase towards 
oligosaccharides with terminal N-sulphated glucosamine. The Vm, ~ for MU-aGlcNS is 
essentially the same as the Vma ~ for the best oligosaccharide, a tetrasaccharide (Hopwood 
and Elliott 1982). This demonstrates that heparin sulphamidase has no absolute require- 
ment for adjacent heparin-specific saccharides for its enzymatic action. Our results uggest 
that the presence of any group linked a-glycosidically toN-sulphoglucosamine s sufficient 
to create a substrate for heparin sutphamidase. However, the K m of our derivatized mono- 
saccharide substrate (4retool/L) is much greater than those for the oligosaccharides: GlcNS- 
IdOA, 35-220#molgL (Hopwood and Elliott 1981a,b; Freeman and Hopwood 1986); 
GlcNS-UA-GlcNS-UOA, 30#mol/L (Hopwood and Elliott 1982): GlcNS-IdoA-GIcNS- 
IdOA, 10#mol/L (Freeman and Hopwood 1986). This suggests that the adjacent saccharides 
contribute to the binding of the substrates, especially at low substrate concentrations. 
Assays with MU substrates requiring more than one enzyme to yield the fluorochrome 
are uncommon. This principle was successfully applied for the first time to a new assay of 
galactose-6-sulphate sulphatase for the diagnosis of Morquio disease type A (Van 
Diggelen et al 1990) and recently for acetyl-CoA:glucosaminide N-acetyltransferase, which 
facilitated the diagnosis of Sanfilippo disease type C (Voznyi et al 1993). This approach 
could also result in replacement ofother cumbersome radiochemical ssays. Potential MU 
substrates for iduronate- and glucuronate-2-sulphatase are currently being synthesized. 
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